30 closest matches · ranked by relevance
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
Bacteremia · Staphylococcus Aureus · Staphylococcus Aureus Bacteremia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…
Staphylococcus Aureus Bacteremia
Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants
Sepsis
Primary: Mortality — 11 Participants
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Staphylococcus Aureus Bacteremia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Sepsis
Primary: Door-to-antibiotic Time — 160; 146; 139; 140 minutes — p=<0.001
Pneumonia Due to Staphylococcus Aureus
Primary: Efficacy Endpoint: All-Cause Mortality by Day 28 — 1; 2; 2; 0 Participants
Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Endocarditis
Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants
Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score
Sepsis · Disease Progression · Septic Shock
Primary: Proportion of the Patients Who Require Vasopressor/Mechanical Ventilator — 53; 21 participants
Gram-Positive Bacterial Infections
Primary: Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With…
Bacteremia
Primary: Cure Rate — 207; 209 Participants
Staphylococcal Infection
Primary: Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) — 45; 16; 2 Participants
Sepsis · Severe Sepsis
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 4 participants
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
Skin/Soft Tissue Infections · Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…
Staphylococcal Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) During Days 1-7 — 2; 1; 17; 4 participants
Pneumonia
Primary: Time to 30-day Mortality — 15; 14 days
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Staphylococcal Infection
Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants
Skin Diseases, Infectious
Primary: Clinical Response at Test of Cure (TOC) — 86.2; 80.0; 0.0; 6.9 Percentage of participants
Sepsis
Primary: Blood Leukocyte Subpopulations: the Absolute Numbers of Leukocytes of Specific Phenotypes — 16.0; 11.2; 11.9; 4.9 10^9 cells/l — p=<0.05
Neonatal Sepsis
Primary: Number of Patients With Adverse Events (AEs) — 3; 3; 0; 0 Participants
Staphylococcal Sepsis
Primary: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35. — 85; 79 Participants
Sepsis
Primary: Antibiotic Treatment for More Than 72 Hours — 33; 55 participants — p=0.002
Bacteremia
Primary: Number of Participants With One or More Adverse Events (AEs) — 15; 6; 12; 9 Participants
MRSA Colonization
Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants